Trial Profile

Phase 1a/1b, first-in-human study of MVX-5005 for the treatment of solid tumors

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 18 Oct 2019

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs MVX 5005 (Primary)
Indications Solid tumours
Focus Adverse reactions; First in man

Most Recent Events

18 Oct 2019 New trial record
14 Oct 2019 According to a SOTIO media release, PPF Group, the majority owner of SOTIO, invests 6.5 million doller as part of MaveriX Oncology's 20 million doller Series A financing round and the proceeds will enable to complete this trial.
14 Oct 2019 According to a SOTIO media release, the company expects to initiate this study by the end of Q4 2020.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com